Pharmaceuticals, Biotechnology and Life Sciences
-Positive 270-day Interim Clinical Study Data for the First Subject and Positive 180-day Interim Clinical Study Data for the Second…
$13.9 million in gross proceeds raised since the beginning of 2024 extending expected cash runway into mid Q1 2025 and…
– Secures $3.2m in PIPE Financing — $50m Term Sheet Obtained for Available Financing under Equity Line of Credit –…
BERKELEY HEIGHTS, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”),…
FORT WORTH, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) — TFF Pharmaceuticals, Inc. (Nasdaq: TFFP) today announced that the Company has…
Obtained agreement from FDA to initiate a Phase 1 trial evaluating multiple doses of Rhenium (186Re) Obisbemeda for the treatment…
DURHAM, N.C., Nov. 14, 2024 (GLOBE NEWSWIRE) — Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated…
BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming…
●Total revenues for the third quarter 2024 were $9.0 million, an increase of 1.5% from Q3 2023. Revenue increase would…
GAITHERSBURG, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a…